Log in to search using one of your social media accounts:


Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy

AUSTIN, Texas and CAMBRIDGE, Mass., April 11, 2018 -- (Healthcare Sales &Marketing Network) -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology plat... Biopharmaceuticals, Oncology, Drug Delivery, Personnel Genprex, Oncoprex, immunogene therapy, non-small cell lung cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Hao S, Du X, Song Y, Ren M, Yang Q, Wang A, Wang Q, Zhao H, Du Z, Zhang G Abstract The incidence of lung cancer and lung cancer-associated mortality have markedly increased worldwide, and gene-targeted therapy has emerged as a promising treatment strategy. The present study aimed to explore the targeted antitumor effect of the herpes simplex virus-thymidine kinase/human interleukin-12 (HSV-TK/hIL-12) fusion gene regulated by the human secretory leukocyte protease inhibitor (hSLPI) promoter of human non-small cell lung cancer (hNSCLC). There were four recombinant eukaryotic expression vectors: pcDNA3.1-CMV-...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Co‑expression of murine double minute 2 siRNA and wild‑type p53 induces G1 cell cycle arrest in H1299 cells. Mol Med Rep. 2017 Oct 11;: Authors: Liu L, Zhang P, Guo H, Tang X, Liu L, Li J, Guo R, Cai Y, Liu Y, Li Y Abstract The therapeutic options available for the treatment of advanced non-small cell lung cancer have increased over the past decade. Small molecule gene therapy has emerged as an effective therapy for the treatment of lung cancer in vitro and in vivo although it has not been tested in a clinical setting. In particular, therapies that target the negative feedback loop betwee...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Y Zhang
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
Cancer Gene Therapy, Published online: 21 April 2017; doi:10.1038/cgt.2017.10
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
This article has been withdrawn at the request of the Editor-in-Chief.Following peer-review and acceptance of the above referenced paper for publication in Lung Cancer, the Editor-in-Chief was contacted by the Editor-in-Chief of the journal, Gene Therapy, with information that the manuscript had simultaneously been submitted to both Lung Cancer and Gene Therapy. A referee selected to review the manuscript for Gene Therapy was also contacted by the Editor-in-Chief of the journal, Respiratory Research, with a request to review the same manuscript for that journal.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
-L Wang
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
Xu &H Guo
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
Abstract: The recently discovered long noncoding RNAs have the potential to regulate many biological processes, which are aberrantly expressed in many tumor types. Our previous study showed that the long noncoding RNA-growth arrest-specific transcript 5 (GAS5) was decreased in lung cancer tissue, which contributed to the proliferation and apoptosis of nonsmall cell lung cancer (NSCLC). GAS5 was also associated with the prognosis of lung cancer patients. These results suggest that GAS5 may represent a novel prognostic indicator and a target for gene therapy in NSCLC. However, the expression and diagnosis significance of GAS...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Diagnostic Accuracy Study Source Type: research
Authors: Huang Q, Li L, Li L, Chen H, Dang Y, Zhang J, Shao N, Chang H, Zhou Z, Liu C, He B, Wei H, Xiao J Abstract Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the five-year survival rate is lower in advanced NSCLC patients. Chemotherapy is a widely used strategy in NSCLC treatment, but is usually limited by poor therapeutic efficacy and adverse effects. Therefore, a new therapeutic regimen is needed for NSCLC treatment. Gene therapy is a new strategy in the treatment of NSCLC. However, the lack of efficient and low toxic vectors remains the major obstacle. Here, we developed a bio...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Predina JD, Keating J, Venegas O, Nims S, Singhal S Abstract Non-small Cell Lung Cancer (NSCLC) remains a deadly disease despite aggressive treatment protocols which incorporate chemotherapy, radiation and surgery. These traditional approaches have reached a plateau in therapeutic benefit. There is emerging evidence suggesting that immunotherapy can serve as an alternative treatment modality for NSCLC. Our group has nearly two decades of experience involving immuno-gene therapy with Ad.hIFN-α and Ad.hIFN-β in human mesothelioma trials, and has observed both safety and efficacy in treatment of Th...
Source: Discovery Medicine - Category: Research Tags: Discov Med Source Type: research
More News: Cancer | Cancer & Oncology | Gene Therapy | Genetics | Lung Cancer | Marketing | Non-Small Cell Lung Cancer